While data from these trials demonstrate improved efficacy in obesity and T2D through the addition of GCGR agonism to GLP-1R/GIPR agonism, whether these synergistic improvements are evident in kidney-related outcomes remains to be determined. Here, GLP1R is linked to obesity disorder.